Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Total Non-Current Liabilities: 2013-2025

Historic Total Non-Current Liabilities for Ocular Therapeutix (OCUL) over the last 7 years, with Sep 2025 value amounting to $137.7 million.

  • Ocular Therapeutix's Total Non-Current Liabilities rose 11.15% to $137.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $137.7 million, marking a year-over-year increase of 11.15%. This contributed to the annual value of $129.3 million for FY2024, which is 1.22% down from last year.
  • Ocular Therapeutix's Total Non-Current Liabilities amounted to $137.7 million in Q3 2025, which was up 4.79% from $131.4 million recorded in Q2 2025.
  • Ocular Therapeutix's Total Non-Current Liabilities' 5-year high stood at $137.7 million during Q3 2025, with a 5-year trough of $86.3 million in Q1 2021.
  • Over the past 3 years, Ocular Therapeutix's median Total Non-Current Liabilities value was $126.1 million (recorded in 2025), while the average stood at $122.9 million.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first soared by 30.52% in 2021, then fell by 5.08% in 2024.
  • Quarterly analysis of 5 years shows Ocular Therapeutix's Total Non-Current Liabilities stood at $96.7 million in 2021, then rose by 11.23% to $107.6 million in 2022, then grew by 21.74% to $130.9 million in 2023, then dropped by 1.22% to $129.3 million in 2024, then grew by 11.15% to $137.7 million in 2025.
  • Its last three reported values are $137.7 million in Q3 2025, $131.4 million for Q2 2025, and $126.1 million during Q1 2025.